| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed30e0cd0f26cf0a06d92a1beefde3f6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-105 |
| filingDate |
2021-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8d00efb4632a48da8a18a738e7d4696
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a44875ca4823425e05b2fd874b268029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_934d6027fe7c8262226cb64895a06b50 |
| publicationDate |
2022-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022023237-A1 |
| titleOfInvention |
Additive and/or synergistic combinations of metformin with nutraceuticals for the prevention, inhibition and treatment of sars-cov-2 and associated covid-19 |
| abstract |
Disclosed are compositions of matter, treatments and protocols useful for prevention of SARS-CoV-2 infection, as well as inhibition of viral propagation and acceleration of viral cure. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at risk of infection with SARS-CoV-2. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19. |
| priorityDate |
2020-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |